Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 6/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15926337 | 0.92 | PLAT (0.47) | PLATALOX5LMNAMAOBMAPT | |
| SCHEMBL1614818 | 0.83 | GPR119 (0.41) | PLATLMNAMAPTALDH1A1KDM4E | |
| SCHEMBL1614661 | 0.79 | LMNA (0.36) | LMNAMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL15926313 | 0.77 | PPARG (0.39) | LMNAMAPTALDH1A1 | |
| SCHEMBL1613899 | 0.75 | PLAT (0.52) | PLATALDH1A1KDM4E | |
| SCHEMBL15926264 | 0.73 | LMNA (0.37) | LMNAMAPT | |
| SCHEMBL1614348 | 0.72 | PLAT (0.56) | PLATMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL1614690 | 0.71 | PLAT (0.52) | PLATMAPTALDH1A1KDM4E | |
| SCHEMBL1279125 | 0.71 | PLAT (0.56) | PLATALDH1A1KDM4E | |
| SCHEMBL1614398 | 0.70 | PLAT (0.49) | PLATLMNAALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796285-B2 | Pyrazolo [1,5-a]-pyrimidones derivatives and pharmaceutical compositions and uses thereof | HEBEI MEDICAL UNIVERSITY (CN) | 2014-08-05 | — | — | US | disclosed |
| US-20120088775-A1 | Pyrazolo-[1,5-a]-Pyrimidones Derivatives and Pharmaceutical Compositions and Uses Thereof | PEKING UNIVERSITY (CN) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088775-A1 | Pyrazolo-[1,5-a]-Pyrimidones Derivatives and Pharmaceutical Compositions and Uses Thereof | KCNJ2, KCNQ5, KCNJ11 | PLAT 1286/4885ALOX5 728/4885LMNA 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.